| Literature DB >> 31061150 |
S Luque1,2,3,4,5, W Hope4,6, N Campillo7,2, R Muñoz-Bermúdez8,9, L Sorli2,3,10,11, J Barceló-Vidal7, E González-Colominas7,5, F Alvarez-Lerma8,9,5, J R Masclans8,9,5, M Montero2,3,10,5, J P Horcajada2,3,10,5, S Grau7,2,3,5.
Abstract
A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.Entities:
Keywords: Candidazzm321990; Monte Carlo simulation; anidulafungin; critical care unit; pharmacokinetics/pharmacodynamics
Mesh：
Substances：
Year: 2019 PMID： 31061150 PMCID： PMC6591598 DOI： 10.1128/AAC.00378-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191